Medicare Price Negotiation Poses Challenges For Safety Net Providers
New drug pricing program under the Inflation Reduction Act could reduce the value of the 340B drug discount for safety net providers by as much as $1 billion in the first year, an analysis by the 340B Health association suggests.
You may also be interested in...
The head of the federal agency overseeing the 340B drug discount program offers unusually direct calls for legislative action during the safety net provider association winter conference. But is action likely in Congress any time soon?
Stakeholders differ on whether the rapid growth in spending is to be expected, given the realities in health care and specialty drug costs, or that the data underscores the need for oversight and reform of the 340B program.
The other seven drugs on the initial list for negotiation are already heavily rebated and CMS could choose not to go much lower than current net prices, SSR Health report points out.